Kestrel Therapeutics
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
127 Western Ave, Allston, Massachusetts,...Website
www.kestreltherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Kestrel Therapeutics
Kestrel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing targeted therapies for intractable cancers driven by KRAS mutations. The company aims to create best-in-class small molecule inhibitors that effectively target KRAS, which is implicated in over 20% of all cancers. Their lead candidate, KST-6051, is an oral pan-KRAS inhibitor that has shown promise in pre-clinical testing and is set to enter Phase 1 clinical trials. Kestrel Therapeutics focuses on leveraging exceptional science to deliver transformative medicines for patients suffering from these challenging cancers.Explore more
Kestrel Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kestrel Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Kestrel Therapeutics
Earning: See what the market has to say on Kestrel Therapeutics recently announced quarterly report
Check if Kestrel Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Kestrel Therapeutics had a recent Job posting/layoffs
Check out if Kestrel Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Kestrel Therapeutics has new funding data
Product Launch: Get notified when Kestrel Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Kestrel Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Kestrel Therapeutics
Find more new buyers
Company Profile Activity
Activity Insights
Kestrel Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Kestrel Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Kestrel Therapeutics.
Kestrel Therapeutics financials insights
Gather financial insights about Kestrel Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Debt
$5M
Kestrel Therapeutics Tech Stack
A closer look at the technologies used by Kestrel Therapeutics
Most Recent Scoops
Person-Based
Partnership
Person-Based
Research & Development, Pharmaceuticals
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Product Development, Legal Affairs, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Project
Laboratory Operations, Medical Research, Clinical Operations
Kestrel Therapeutics News & Media
Kestrel Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, in Patients with KRAS-driven Malignancies
Kestrel has entered into a warrant agreement with AbbVie with an exclusive option for AbbVie to acquire the Company based on defined development milestones Kestrel has entered into a warrant agreement with AbbVie with an exclusive option for AbbVie to acquire the Company based on defined development milestonesKestrel Therapeutics Announces IND Clearance by U.S. FDA of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, Enabling Initiation of Phase 1 Trial
WATERTOWN, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Kestrel Therapeutics Inc. (“Kestrel” or the “Company”), a clinical stage biotechnology company developing next-generation small-molecule inhibitors targeting mutant KRAS, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for KST-6051, an investigational, oral, small-molecule inhibitor designed to target KRAS.
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Kestrel Therapeutics
Sign Up For FreeTo access detailed company insights
Kestrel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing targeted therapies for intractable cancers driven by KRAS mutations. The company aims to create best-in-class small molecule inhibitors that effectively target KRAS, which is implicated in over 20% of all cancers. Their lead candidate, KST-6051, i... Read More
